Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis

Journal of Infection and Chemotherapy

Volumn 17, Issue 6, 2011, Pages 831-841

  Ohata, Yuka ^a   Tomita, Yoshiko ^a   Nakayama, Mitsunobu ^a   Tamura, Kazuo ^b   Tanigawara, Yusuke ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

T > MIC; Febrile neutropenia; Meropenem; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CREATININE; MEROPENEM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM IDENTIFICATION; BLOOD SAMPLING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL; POPULATION MODEL; SEX RATIO; TREATMENT DURATION;

EID: 84855273156     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0271-9     Document Type: Article

References (24)

1. JL Kuti PK Dandekar CH Nightingale DP Nicolau 2003 Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem J Clin Pharmacol 43 1116 1123 14517194 10.1177/0091270003257225 1:CAS:528:DC%2BD3sXot1Wjsrc%3D (Pubitemid 37174443)
2. HM Mattoes JL Kuti GL Drusano DP Nicolau 2004 Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem Clin Ther 26 1187 1198 15476901 10.1016/S0149-2918(04)80001-8 1:CAS:528:DC%2BD2cXos1egu7k%3D (Pubitemid 39445343)
3. C Li JL Kuti CH Nightingale DP Nicolau 2006 Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients J Clin Pharmacol 46 1171 1178 16988206 10.1177/0091270006291035 1:CAS:528: DC%2BD28XhtFeitL%2FM (Pubitemid 44387417)
4. JL Kuti C Ong M Lo D Melnick N Soto DP Nicolau 2006 Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections Int J Antibicrobial Agents 28 62 68 10.1016/j.ijantimicag.2006.02.018 1:CAS:528:DC%2BD28Xmt1Gku7c%3D (Pubitemid 43949338)
5. LS Filho KJ Eagye JL Kuti DP Nicolau 2007 Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy Clin Microbiol Infect 13 579 585 10.1111/j.1469-0691.2007.01693.x (Pubitemid 46730663)
6. A Watanabe S Fujimura T Kikuchi K Gomi K Fuse T Nukiwa 2007 Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation J Infect Chemother 13 332 340 17982723 10.1007/s10156-007-0562- 3 1:CAS:528:DC%2BD2sXht1Glu7zE (Pubitemid 350059926)
7. H Mikamo K Totsuka 2005 The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation Jpn J Antibiot 58 159 167 15997656 (Pubitemid 40628379)
8. DG Lee SM Choi WS Shin HO Lah DS Yim 2006 Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea Int J Antimicrob Agents 28 333 339 16942864 10.1016/j.ijantimicag.2006.05.033 1:CAS:528: DC%2BD28XpvFGis7Y%3D (Pubitemid 44402998)
9. H Wang B Zhang Y Ni JL Kuti B Chen M Chen, et al. 2007 Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003-2004 Int J Antimicrob Agents 30 452 457 17646088 10.1016/j.ijantimicag.2007.06.005 1:CAS:528:DC%2BD2sXhtFers7rL (Pubitemid 47498959)
10. Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa S, Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic consideration. Drug Metab Pharmacokinet (in press).
11. C Li X Du JL Kuti DP Nicolau 2007 Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Antimicrob Agents Chemother 51 1725 1730 17307978 10.1128/AAC.00294-06 1:CAS:528:DC%2BD2sXlt1yjsLg%3D (Pubitemid 46744151)
12. K Ikawa N Morikawa H Ohgi K Ikeda T Sueda M Taniwaki, et al. 2010 Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients J Infect Chemother 16 25 32 20082106 10.1007/s10156-009-0022-3 1:CAS:528:DC%2BC3cXhslektr4%3D
13. RE Ariano A Nyhlén JP Donnelly DS Sitar GKM Harding SA Zelenitsky 2005 Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia Ann Pharmacother 39 32 38 15598967 1:CAS:528: DC%2BD2MXmvVShsw%3D%3D (Pubitemid 40052375)
14. K Yamaguchi Y Ishii M Iwata N Watanabe N Uehara M Yasujima, et al. 2007 Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006 Jpn J Antibiot 60 344 377 18447206 1:CAS:528:DC%2BD1cXhs1ehtrk%3D (Pubitemid 351154892)
15. Clinical phase 3 study of meropenem. Pharmaceuticals and medical devices agency, Japan [CTD, common technical document] 2010. http://www.info.pmda.go.jp/ shinyaku/P201000014/index.html.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard M7-A7. CLSI, Wayne, PA, 2006.
17. Guidance for Industry: Population Pharmacokinetics. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (U.S.) (February 1999).
18. Guideline on Reporting the Results of Population Pharmacokinetic Analyses. European Medicines Agency (UK) (January 2008).
19. Nakajima M, Uematsu T, Kanamaru M. Clinical phase Ι study of meropenem. Chemotherapy 1992;40(S-I):258-275.
20. BA Christensson I Nilsson-Ehle M Hutchison SJ Haworth B Oqvist SR Norrby 1992 Pharmacokinetics of meropenem in subjects with various degrees of renal impairment Antimicrob Agents Chemother 36 1532 1537 1510451 1:CAS:528: DyaK38XkvVarurY%3D
21. M Chimata M Nagase Y Suzuki M Shimomura S Kakuta 1993 Pharmacokinetics of meropenem in patients with carious degrees of renal function, including patients with end-stage renal disease Antimicrob Agents Chemother 37 229 233 8452352 1:STN:280:DyaK3s7pvFaqsQ%3D%3D (Pubitemid 23046560)
22. T Shibayama D Sugiyama E Kamiyama T Tokui T Hirota T Ikeda 2007 Characterization of CS-023 (R04908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters Drug Metab Pharmacokinet 22 1 41 47 17329910 10.2133/dmpk.22.41 1:CAS:528: DC%2BD2sXksF2luro%3D
23. R Tsumura K Ikawa M Morikawa K Ikeda M Shibukawa K Iida, et al. 2008 The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients J Chemother 20 5 615 621 19028626 1:CAS:528: DC%2BD1cXhsFemsLvO
24. Hathorn WJ, Lyke K. Empirical treatment of febrile neutropenia: Evolution of current therapeutic approaches. Clin Infect Dis 1997;24(suppl 2):s256-s265. (Pubitemid 27130715)